Oppilotech

Oppilotech Ltd is a biotechnology company founded in 2014 by a team including Dr. Ajay Mistry (CEO), Dr. John George (CSO), and Keith Powell (Chairman). The founders bring extensive experience from the pharmaceutical, biotech, and academic sectors, covering research and development, drug discovery, and investment management. The company was established based on the computational modeling work initiated by Dr. John George, which originally focused on the biochemistry of E. coli membranes.

Oppilotech operates in the biotechnology sector, serving pharmaceutical and biotech firms by providing a proprietary computational platform that combines systems biology and machine learning. This high-resolution platform simulates complex biological processes within cells to identify viable, first-in-class drug targets, which is crucial for developing new medicines. The company has built some of the most detailed computational models of bacteria ever assembled. While its initial focus was on developing novel antibacterial therapies to combat antimicrobial resistance (AMR), Oppilotech also has early-stage oncology programs based on its modeling of cancer cells.

The company's business model centers on collaborative partnerships and licensing agreements, generating revenue through service fees and royalties from successful drug discoveries. It offers its advanced biochemical modeling capabilities as a service to provide clients with a deeper understanding of their targets, pathways, or compounds of interest. Oppilotech has received funding from various entities, including a Seed round of $483K from CARB-X and grants from Innovate UK, the UK's innovation agency. Headquartered in London, the company maintains research laboratories in Stevenage.

Keywords: drug discovery, computational biology, systems biology, machine learning, biotechnology, antibacterial, drug targets, predictive modelling, antimicrobial resistance, first-in-class drugs, cell simulation, biochemical modeling, pharmaceutical partnerships, drug development, oncology, Gram-negative bacteria, computational platform, microbiology services, predictive analytics, cell metabolism